KeViRx is a preclinical pharmaceutical company with a PTP4A3 phosphatase-targeted platform technology (i.e., pipeline in a molecule).
Leuko is an MIT spinout developing PointCheckTM, the world’s first medical device that can monitor white blood cells non-invasively. By enabling more frequent at-home monitoring, Leuko aims to improve clinical outcomes for more than 2M cancer chemotherapy patients a year, reduce their chemotherapy-related hospital readmissions by 50% and save >$6B annually in healthcare cost.